Suppr超能文献

乙型肝炎病毒前 S2 突变患者肝细胞癌中调节性 T 细胞浸润增加。

Increased infiltration of regulatory T cells in hepatocellular carcinoma of patients with hepatitis B virus pre-S2 mutant.

机构信息

Graduate Institute of Biomedical Sciences, China Medical University, No. 91, Hsueh-Shih Rd., Northern Dist., Taichung City, 404, Taiwan, ROC.

Organ Transplantation Center, China Medical University Hospital, Taichung, Taiwan, ROC.

出版信息

Sci Rep. 2021 Jan 13;11(1):1136. doi: 10.1038/s41598-020-80935-5.

Abstract

Hepatocellular carcinoma (HCC) is a frequent and deadly human cancer worldwide that is intimately associated with chronic hepatitis B virus (HBV) infection. Pre-S2 mutant is a HBV oncoprotein that plays important roles in HCC development and is linked to poor prognosis in HCC patients. However, the profiles of tumor-infiltrating lymphocytes in HCC tissues of pre-S2 mutant-positive patients remain unknown. In this study, we performed fluorescent immunohistochemistry staining to detect the infiltration of 'anti-tumor' cytotoxic T lymphocytes (CTLs) and 'pro-tumor' regulatory T cells (Tregs) in pre-S2 mutant-positive and -negative HCC patients. We showed that pre-S2 mutant-positive patients had a significantly higher infiltration of CD4CD25 cells and forkhead box P3 (Foxp3)-expressing cells but similar CTLs and lower granzyme B-expressing cells in HCC tissues compared with pre-S2 mutant-negative patients. Moreover, the percentage of pre-S2 plus pre-S1 + pre-S2 deletion (pre-S2 mutant) was positively correlated with the density of CD4CD25 cells and Foxp3-expressing cells but negatively with granzyme B-expressing cells in HCC tissues. Considering that increased intratumoral Tregs have been shown to promote tumor immune evasion, our data may provide new insights into the pathogenesis of HBV pre-S2 mutant-induced HCC and suggest that therapeutics targeting Tregs may be a promising strategy for treating pre-S2 mutant-positive high-risk patient population.

摘要

肝细胞癌 (HCC) 是一种常见且致命的人类癌症,与慢性乙型肝炎病毒 (HBV) 感染密切相关。Pre-S2 突变体是一种 HBV 癌蛋白,在 HCC 发展中发挥重要作用,并与 HCC 患者的预后不良相关。然而,Pre-S2 突变阳性患者的 HCC 组织中浸润淋巴细胞的特征尚不清楚。在这项研究中,我们进行了荧光免疫组织化学染色,以检测 Pre-S2 突变阳性和阴性 HCC 患者中“抗肿瘤”细胞毒性 T 淋巴细胞 (CTLs)和“促肿瘤”调节性 T 细胞 (Tregs)的浸润情况。结果显示,与 Pre-S2 突变阴性患者相比,Pre-S2 突变阳性患者的 HCC 组织中 CD4CD25 细胞和叉头框 P3 (Foxp3)表达细胞的浸润显著增加,但 CTLs 相似,颗粒酶 B 表达细胞较低。此外,Pre-S2 加 Pre-S1+Pre-S2 缺失 (Pre-S2 突变) 的百分比与 HCC 组织中 CD4CD25 细胞和 Foxp3 表达细胞的密度呈正相关,与颗粒酶 B 表达细胞呈负相关。考虑到肿瘤内 Tregs 的增加已被证明可促进肿瘤免疫逃逸,我们的数据可能为 HBV Pre-S2 突变诱导 HCC 的发病机制提供新的见解,并表明针对 Tregs 的治疗可能是治疗 Pre-S2 突变阳性高危患者人群的一种有前途的策略。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2e77/7807072/185047f718de/41598_2020_80935_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验